OMT-28

Asset

Activates the AMPK/SIRT1/PGC1-alpha axis to reduce mitochondrial dysfunction, oxidative stress and inflammation.

Stage: Phase 2
Modality: Small molecule
Target: Mitochondrial biogenesis (PGC-1α); 4
Indications: 3
Trials: 1
Developer

Indications

4

Primary mitochondrial disease
Phase 2, omeicos.com, 10 Oct 2026
Chronic inflammation in coronary artery disease
Preclinical, omeicos.com, 10 Oct 2026
Wet AMD
Preclinical, omeicos.com, 10 Oct 2026

1 more

In the full profile

Targets and what it contains3
Owner and partners1
Trials3
Evidence for its targets3
Competitors9
Aging relevance2

Every asset’s record: target, stage, trials and the evidence behind it.